Zacks Investment Research
10 Jul 2026, 17:46 UTC · 3h ago
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Jul 2026, 17:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Neurocrine Biosciences (NBIX) has a projected earnings per share (EPS) growth rate of 48.3% for the current year. — Projected growth significantly exceeding the industry average (14.4%) is a strong positive catalyst for a growth-oriented biopharmaceutical stock.
+0.40Neurocrine Biosciences currently holds a top Zacks Rank (Strong Buy or Buy) and a favorable Growth Style Score. — Positive proprietary rankings from a known research entity typically increase short-term buying interest and risk appetite for the specific security.
+0.20Which stocks this story touches
The company is recommended as a great growth pick with a top Zacks Rank and projected earnings growth that crushes the industry average.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
6h ago
